Analyst Ratings.Net shows that Integra Lifesciences has been given a consensus rating of "buy" by the seven ratings firms that are currently covering the company, according to a report by The Legacy.
Here are four things to know about the company's stock:
• The average one-year price target is $64.57, among brokers who have revised their coverage on the stock in the last year.
• The company has a one-year low of $43.55 and a one-year high of $63.
• The stock's 50-day moving average is $60 and its 200-day moving average is $54.
• The company has a market cap of $2.03 billion.